Home » Authors » James Etheridge

Articles by James Etheridge

LibraGen Enters Research Deal With Sanofi-Aventis

Nov. 1, 2006

By James Etheridge

Innate Planning For IPO, Seeking €25M To €36M

Nov. 1, 2006

By James Etheridge

Cytheris' €24M Series B Round Should Fuel Company Into 2009

Nov. 1, 2006

By James Etheridge

Innate Planning For IPO, Seeking €25M To €36M

Nov. 1, 2006

By James Etheridge

No Abstract

LibraGen Enters Research Deal With Sanofi-Aventis

Nov. 1, 2006

By James Etheridge

Cytheris' €24M Series B Round Should Fuel Company Into 2009

Nov. 1, 2006

By James Etheridge

No Abstract

BioAlliance Pharma Receives Loramyc Marketing Approval

Oct. 18, 2006

By James Etheridge

BioAlliance Pharma Receives Loramyc Marketing Approval

Oct. 18, 2006

By James Etheridge

Innate Pharma Selects New Drug For Preclinical Program

Oct. 11, 2006

By James Etheridge

Faust Brings In €8M Bridge Financing, Aims For More

Oct. 11, 2006

By James Etheridge

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...